Healthcare

PREDICTION BY

FOLLOW-UP

GLP-1-based drugs saw massive uptake and media coverage in 2024–2025, with significant impacts on pharma revenues, consumer behavior, and expectations for obesity treatment. Measurable indicators suggest GLP-1 drugs had very substantial real-world impact, arguably more directly felt in everyday lives than GPT-4 for many people in 2024–2025, despite GPT-4's major influence in its own domain.

PREDICTION BY

FOLLOW-UP

GLP-1 weight-loss drugs became a major economic and societal storyline in 2024-2025, impacting health, consumer behavior, and equity markets. While AI models also had large impacts, GLP-1's effect on healthcare, consumer categories, and capital markets was arguably at least as visible, making the prediction directionally accurate.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs continued explosive growth in prescriptions and revenue through 2024-2025, with major CPG and food companies citing their impact on earnings calls. Media coverage frequently framed GLP-1 drugs as one of the most impactful technologies affecting health and consumer behavior.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs have indeed shown explosive growth and broad economic effects, supporting the direction of high impact. However, the comparative claim of 'even more impact on the global economy this year than AI' is subjective and not cleanly verifiable with objective economic data. Both AI and GLP-1 are considered major economic drivers.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive adoption and major impact on consumer behavior and industries, as predicted. While AI also remained prominent, the significant impact of GLP-1 drugs in 2024 supports the \"year of GLP-1\" claim.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive growth and became a central theme in business and health coverage in 2024, influencing consumer behavior and industry discussions, consistent with Galloway's prediction of them being a defining 'tech of the year'.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive growth and became a central theme in business and health coverage in 2024, influencing consumer behavior and industry discussions, consistent with Galloway's prediction of them being a defining 'tech of the year.'

PREDICTION BY

FOLLOW-UP

GLP-1 drugs did become one of the most economically and culturally significant technologies in 2024, at least on par with mainstream AI coverage in business and consumer media.

PREDICTION BY

FOLLOW-UP

AI adoption in healthcare (diagnostics, clinical support, administration) has accelerated, with tech giants investing heavily. While a full 'revolution' in the system's structure has not occurred, early evidence points towards the long-term disruption outlined, making it an evolving prediction.

PREDICTION BY

FOLLOW-UP

The COVID-19 pandemic significantly accelerated the adoption of telemedicine and on-demand consultations, proving this prediction accurate.